SSB-4, a Non-Antibody Inhibitor Blocks Binding of SARS-CoV-2 to ACE2
SSB-4 is a non-antibody biologics specifically engineered for blocking the infection of the coronavirus SARS-CoV-2 by abolishing interaction between viral spike protein with ACE2 which is the gateway of virus entry into human cells. Our candidate molecule contains all human sequence, exhibits a single digit nanomolar affinity, and is highly efficacious in blocking pseudovirus infection on ACE2 expression cells.
If you are interested in SSB-4 project, please contact us.
Recombinant protein as a Pan Fc Receptor Interacting molecule
Cancer treatment via symbiosis with tumor tissues through slowing down the progression of cancer-triggered cachexia.
Massive antibody mining, an unique platform for accelerating R&D timelines of therapeutic antibodies.
a Non-Antibody Biologics engineered for Blocking of SARS-CoV-2 Binding to ACE2.
Next generation CAR-T modules.
Niche platform technology for life cycle maintenance of approved antibody drugs.